SavedAdd your journal

Journals / Journal of Microbiology and Infectious Diseases / 2016 / Cilt: 6 - Sayı: 1

Treatment of Acute Hepatitis C

İlkay BOZKURT
Pages
40–44
Publication Date
2016-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

J Microbiol Infect Dis 2016;6(1): 40-44

📌 3 Key Takeaways

🎯
Objective & Hypothesis:An acute hepatitis C virus (HCV) infection is an uncommonly encountered illness.
📊
Key Findings & Data:Advances in the treatment options of chronic HCV infection have resulted in the development of many new antiviral drugs that may allow for simplified and shortened treatments with increased tolerability and efficacy in patients with acute HCV infection.
💡
Conclusion & Impact:J Microbiol Infect Dis 2016;6(1): 40-44
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Acute hepatitis C · treatment · genotype

Abstract

An acute hepatitis C virus (HCV) infection is an uncommonly encountered illness. Patients infected with the HCV commonly tend to be asymptomatic because of spontaneous viral clearance or chronic infection. Early antiviral treatment may be beneficial especially in symptomatic cases. Antiviral therapy with an (IFN)-based regimen is standard except in the instance of a human immunodeficiency virus (HIV) coinfection. The efficacy of HCV therapy has been restricted by the side effects of treatment. Advances in the treatment options of chronic HCV infection have resulted in the development of many new antiviral drugs that may allow for simplified and shortened treatments with increased tolerability and efficacy in patients with acute HCV infection. J Microbiol Infect Dis 2016;6(1): 40-44

🔖

Cite This Article

BOZKURT, İ. (2016). Treatment of Acute Hepatitis C. Journal of Microbiology and Infectious Diseases, Cilt: 6 - Sayı: 1, 40–44. https://ajindex.com/articles/100830

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-1297
  2. Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Semin Liver Dis 2012;32:130-137
  3. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Di. 2005;40:951-958
  4. European Association for the Study of the Liver (EASL) Available from: URL:
  5. Irving WL, Salmon D, Boucher C, et al. Acute hepatitis C virus infection. Euro Surveill 2008;13:18879
  6. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Di 2005;9:383-398
  7. Chung RT. Acute hepatitis C virus infection. Clin Infect Dis 2005;41:14-17
  8. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother 2010;65:4-9
  9. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepa. 2006;13:34-41
  10. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88
  11. Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003;37:60-64
  12. Corey KE, Mendez-Navarro J, Gorospe EC, et al. Early treatmentimproves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010;17:201-217
  13. Licata A, Di Bona D, Schepis F, et al. When and how to treat acute hepatitis C? J Hepatol 2003;39:1056-1062
  14. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-638
  15. Deterding K, Grüner N, Buggisch P, et al. Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013;13:497-506
  16. Broers B, Helbling B, François A, et al. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-328
  17. Wiegand J, Deterding K, Cornbe